Abstract
The modern era of chemotherapy for patients with cancer began fifty years ago when Farber et al. reported on the use of aminopterin to induce a temporary remission in acute lymphoblastic leukemia in children [1]. Although aminopterin is not in common usage at this time, folic acid antagonists remain amongst the most widely used antineoplastic agents. Methotrexate is the most frequently used drug of this group and is a mainstay in the treatment of common childhood malignancies. It is an integral component of therapy for patients being treated for acute lymphoblastic leukemia and Non-Hodgkin’s Lymphoma and is often used in the treatment of patients with osteogenic sarcoma.
Chapter PDF
Similar content being viewed by others
Keywords
- Acute Lymphoblastic Leukemia
- Dose Methotrexate
- Intrathecal Methotrexate
- Childhood Acute Lymphoblastic Leukemia
- Childhood Malignancy
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
References
Farber S, Diamond L, Mercer R, Sylvester RF, Wolff JA (1948) Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4 amino-pteroyl-glutamic acid (aminopterin). N Engl J Med 238: 787–793
Bertino JR, Kamen BA (1996) Chemotherapeutic Agents: Folic Acid Antagonists. In: Holland JF, Frei E, Bast RC, Kufe DW, Morton DL, Weichselbaum RR (eds): Cancer Medicine. Lea and Febiger, Philadelphia and London, 907–928
Crom W (1998) Methotrexate. In: Grochow L, Ames M (eds): A clinician’s guide to chemotherapy pharmacokinetics and pharmacodynamics. Williams and Wilkins, 311–330
Kamen BA (1997) Folate and Antifolate Pharmacology. Sem Oncol 24: 18–39
Blount BC, Mack MM, Wehr CM, MacGregor JT, Hiatt RA, Wang G, Wickramasinghe SN, Everson RB, Ames BN (1997) Folate deficiency causes uracil mis-incorporation into human DNA and chromosome breakage: Implications for cancer and neuronal damage. Proc Natl Acad Sci USA 94: 3290–3295
Quinn CT, Kamen BA (1996) A biochemical perspective of methotrexate neurotoxicity with insight on non-folate rescue modalities. J Invest Med 44: 522–530
Huennekens FM (1994) The methotrexate story: a paradigm for development of cancer therapeutic agents. Adv Enz Reg 34: 397–419
Smith AS, Hum M, Winick NJ, Kamen BA (1996) A case for the use of aminopterin in treatment of patients with leukemia based upon metabolic studies of blasts in vitro. Clin Cancer Res 2: 69–73
Ratliff AF, Wilson J, Hum M, Marling-Cason M, Rose K, Winick N, Kamen BA (1998) A phase I and pharmacokinetic trial of aminopterin in patients with refractory malignancies. J Clin Oncol 16: 1458–1464
Zhang L, Taub JW, Williamson M, Wong SC, Hukku B, Pullen J, Ravindranath Y, Matherly LH (1998) Reduced Folate carrier gene expression in childhood acute lymphoblastic leukemia: relationship to immunophenotype and ploidy. Clin Cancer Res 4: 2169–2177
Egan MG, Sirlin S, Rumberger BG, Garrow TA, Shane B, Sirotnak FM (1995) Rapid decline in folylpolyglutamate synthetase activity and gene expression during maturation of HL-60 cells. J Biol Chem 270: 5462–5468
Lark RH, Smith AS, Kamen BA (1996) Folylpolyglutamate Synthetase but not folate receptor correlates with MA104 cell growth in vitro. Cancer Res Ther Control 5: 1–10
Weitman SD, Weinberg AG, Coney LR, Zurawski VR, Jennings D, Kamen BA (1992) Cellular localization of the folate receptor: Potential role in drug toxicity and folate homeostasis. Cancer Res 52: 6708–6711
Weitman S, Anderson RGW, Kamen BA (1994) Folate binding proteins. In: K. Dakshinamurti (ed): Vitamin receptors: vitamins as ligands in cell communication. Cambridge. University Press Cambridge, 106–136
Gorlick R, Goker E, Trippett T, Steinherz P, Elissesyeff Y, Mazumdar M, Flintoff WF, Bertino JR (1997) Defective transport is a common mechanism of acquired methotrexate resistance in acute lymphocytic leukemia and is associated with decreased reduced folate carrier expression. Blood 89: 1013–1018
Chazal M, Cheradame S, Formento JL, Francoual M, Formento P, Etienne MC, Francois E, Richelme H, Mousseau M, Letoublon C, et al (1997) Decreased folypolyglutamate synthetase in tumors resistant to fluorouracil-folinic acid treatment: Clinical data. Clin Cancer Res 3: 553–557
Rhee MS, Wang Y, Nair MG, Galivan J (1993) Acquisition of resistance to antifolates caused by enhanced gamma-glutamyl hydrolase activity. Cancer Res 53: 2227–2230
Pui C-H, Evans WE (1998) Acute lymphoblastic leukemia. N Engl J Med 339: 605–615
Simone J (1998) The evolution of cancer care for children and adults. J Clin Oncol 16: 2904–2905
Law LW (1952) Effects of combinations of antileukemic agents on an acute lymphocytic leukemia of mice. Cancer Res 12: 871–878
Goldin A, Mantel N, Greenhouse SW, Venditti JM, Humphreys SR (1953) Effect of delayed administration of citrovorum factor on the antileukemic effectiveness of aminopterin in mice. Cancer Res 13: 43–48
Goldin A, Venditti JM, Humphreys SR, Mantel N Modification of treatment schedules in the management of advanced mouse leukemia with aminopterin. J Natl Can Inst 17: 203–212
Frei E, Freirech EJ, Gehan E, Pinkel D, Holland JF, Selawry O, Haurani F, Spurr CL, Hayes DM, James W, Rothberg H, et al (1961) Acute leukemia group B, studies of sequential and combination antimetabolite therapy in acute leukemia: 6 mercaptopurine and methotrexate. Blood 18: 431–454
Jonsson OG, Kamen BA (1991) Methotrexate and Childhood Leukemia. Cancer Invest 9: 53–60
Ackland SP, Schilsky RL (1987) High-dose methotrexate: A critical reappraisal. J Clin Oncol 5: 2017–2031
Lange BJ, Blatt J, Sather HN, Meadows AT (1996) Randomized comparison of moderate-dose methotrexate infusions to oral methotrexate in children with intermediate risk acute lymphoblastic leukemia: a children’s cancer study group. Med Pediatr Oncol 27: 15–20
Seidel H, Nygaard R, Moe PJ, Jacobsen G, Lindqvist B, Slordal L (1997) On the prognostic value of systemic methotrexate clearance in childhood acute lymphoblastic leukemia. Leukemia Res 21: 429–434
Evans WE, Crom WR, Abromowitch M, Dodge R, Look AT, Bowman WP, George SL, Pui CH (1986) Clinical pharmacodynamics of high-dose methotrexate in acute lymphoblastic leukemia. N Engl J Med 314: 471–477
Freeman AI, Weinberg V, Brecher ML, et al (1983) Comparison of intermediate dose methotrexate with cranial irradiation for the post-induction treatment of acute lymphocytic leukemia in children. N Engl J Med 308: 477–484
Abromowitch M, Ochs J, Pui CH, Fairclough D, Murphy SB, Rivera G (1988) Efficacy of high dose methotrexate in childhood acute lymphocytic leukemia: Analysis by contemporary risk classifications. Blood 71: 866–869
Mahoney DH, Shuster J, Nitschke R, Lauer SJ, Winnick N, Steuber CP, Camitta B (1998) Intermediate — Dose Methotrexate with intravenous mercaptopurine is superior to repetitive low-dose oral methotrexate with intravenous mercaptopurine for children with lower-risk B-lineage acute lymphoblastic leukemia: A Pediatric Oncology Group Phase III Trial. J Clin Oncol 16: 246–254
Kamen BA, Winnick N, Holcenberg JS (1998) Oral vs. intravenous methotrexate: Another opinion. J Clin Oncol 16: 2283–2284
Mahoney DH, Shuster JJ, Nitschke R, Lauer SJ, Steuber CP, Winick W, Camitta B (1998) Acute neurotoxicity in children with B-precursor acute lymphoblastic leukemia: an association with intermediate-dose intravenous methotrexate and intrathecal triple therapy — a pediatric oncology group study. J Clin Oncol 16: 1712–1722
Kamen BA, Vietti T (1989) Oral Leucovorin increases CSF folate concentration in children with leukemia. Brit J Cancer 60: 799
Nachman JB, Sather HN, Sensel MG, Trigg ME, Cherlow JM, Lukens JN, Wolff L, Uckun FM, Gaynon P (1975) Augmented post-induction therapy for children with high-risk lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med 338: 1663–1671
Capizzi RL (1975) Improvement in the therapeutic index of methotrexate by 1-asparaginase. Cancer Chem Rep 6: 37–41
Balis FM, Holcenberg JS, Poplack DG, Ge J, Sather HN, Murphy RF, Ames MM, Waskerwitz MJ, Tubergen DG, Zimm S, et al (1998) Pharmacokinetics and pharmacodynamics of oral methotrexate and mercaptopurine in children with lower risk acute lymphoblastic leukemia: A joint Children’s Cancer Group and Pediatric Oncology Branch Study. Blood 92: 3569–3577
Evans WE, Relling MV, Rodman JH, Crom WR, Boyett JM, Pui CH (1998) Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med 338: 499–505
Hum M, Smith A, Lark R, Winick N, Kamen BA (1997) Evidence for negative feedback of extracellular methotrexate (methotrexate) on Acute lymphoblastic leukemia blasts in vitro. Pharmacotherapy 17: 1260–1266
Kamen BA, Holcenberg JS, Turo K, Whitehead VM (1984) Methotrexate and folate content of erythrocytes in patients receiving oral vs. intramuscular therapy with methotrexate. J Pediatr 104: 131–133
Sansone G (1954) Pathomorphosis of acute infantile leukemia treated with modern therapeutic agents; “meningoleukaemia” and Frolich’s obesity. Annales Paediatrici 183: 33–42
Pinkel D (1979) Treatment of acute lymphocytic leukemia. Cancer 43: 1128–1137
Pui CH, Mahmoud HM, Rivera G, Hancock ML, Sandlund JT, Behn FG, Head DR, Relling MV, Ribeiro RC, Rubnitz JE, et al (1998) Early intensification of intrathecal chemotherapy virtually eliminates central nervous system relapse in children with acute lymphoblastic leukemia. Blood 92: 411–415
Balis FM, Lester CM, Chrousos GP, Heideman RL, Poplack DG (1987) Differences in cerebrospinal fluid penetration of corticosteroids: Possible relationship to the prevention of meningeal leukemia. J Clin Oncol 5: 202–207
Peylan-Ramu N, Poplack DG, Blei CL, et al (1977) Computer assisted tomography in methotrexate encephalopathy. J Comput Assist Tomogr 1:216
Wollner N, Burchenal JH, Liebermann PH, Exelby P, D’Angìo G, Murphy ML (1976) Non-Hodgkin’s Lymphoma in children: a comparative study of two modalities of therapy. Cancer 37: 123–134
Meadows AT, Sposto R, Jenkin RDT, Kersey JH, Chilcote RR, Siegel SE, Coccia PF, Rosen-stock J, Pringle KC, Stolar CJ (1989) Similar efficacy of 6 and 18 months of therapy with four drugs for localized non-Hodgkin’s lymphoma of children. A report from the Children’s Cancer Study Group. J Clin Oncol 7: 92–99
Grem JL, King SA, Wittes RE, Jones BL (1988) The role of methotrexate in osteosarcoma. J Natl Cancer Inst 80: 626–656
Bacci G, Picci P, Ruggieri P, Mercuri M, Avella M, Capanna R, Brach Del Prever A, Mancini A, Gherlinzoni F, Padovani G, et al (1990) Primary Chemotherapy and Delayed Surgery for Osteosarcoma of the extremities. Cancer 65: 2539–2553
Krailo M, Ertel I, Makley J, Fryer CJH, Baum E, Weetman R, Yunis E, Barnes L, Bleyer WA, Hammond D (1987) A randomized study comparing high-dose methotrexate with moderate dose methotrexate as components of adjuvant chemotherapy in childhood non-metastatic osteosarcoma: A report form the Childrens Cancer Study Group. Med Pediatr Oncol 15: 69–77
Rosen G, Huvos AG, Mosende C, Beattie EJ, Exelby PR, Capparos B, Marcove RC (1978) Chemotherapy and thoracotomy for metastatic osteogenic sarcoma: a model for adjuvant chemotherapy and the rational for timing of thoracic surgery. Cancer 41: 841–849
Kamen BA, Winick NJ (1988) High dose methotrexate: insecure rationale? Biochem Pharmacol 37: 2713–2715
Bertino JR (1993) Ode to methotrexate. J Clin Oncol 11: 5–14
Kamen BA, Nylen PA, Whitehead VM, Abelson HT, Dolnick BJ, Peterson DW (1985) Lack of dihydrofolate reductase in human tumor and leukemia cells in vivo. Cancer Drug Delivery 2: 133–138
Schifeling DJ, George T, McGuirt F, Capizzi RL, and Kamen BA (1994) Methotrexate (methotrexate) content in squamous cell carcinoma of the head and neck (SCCHN) after low dose methotrexate. Med Pediatr Oncol 22: 88–90
Zachariae H, Kragballe K, Sogaard H (1980) Methotrexate induced cirrhosis. Br J Dermatol 102: 407–412
Kamen BA (1987) Folic acid antagonists. In: Prough RA, Powis G (eds): Metabolism of Anti-Cancer Drugs. Taylor and Francis, Ltd, 141–162
Farrow AC, Buchanan GR, Zwiener JZ, Bowman WP, Winick NJ (1997) Serum aminotransferase elevation during and following treatment of childhood acute lymphoblastic leukemia. J Clin Oncol 15: 1560–1566
Sostman HD, Matthay RA, Putnam C, Smith GJ (1976) Methotrexate induced pneumonitis. Medicine (Baltimore) 55: 371–388
Evans WE, Pratt CB (1978) Effect of pleural effusion on high-dose methotrexate kinetics. Clin Pharmacol Ther 23: 68–72
Cronstein BN, Eberle MA, Griber HE, Levin RI (1991) Methotrexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells. Proc Natl Acad Sci USA 88: 2441–2445
Kane BJ, Kuhn JG, Roush MK (1991) Pentostatin: an adenosine deaminase inhibitor for the treatment of hairy cell leukemia. Ann Pharmacother 26: 939–947
Bemini JC, Fort DW, Griener JC, Kane BJ, Chappell WB, Kamen BA (1995) Aminophylline for methotrexate induced neurotoxicity. Lancet 345: 544–547
Haider K, Wright J, Lemke S, Gentile T (1998) Reversal of methotrexate induced neurotoxicity by the use of iv aminophylline. First case report in adults. Blood 92 suppl: 237a
Boetz MI, Young SN, Bachevalier J, Gauthier S (1979) Folate deficiency and decreased brain 5-hydroxytryptamine synthesis in man and rat. Nature 278: 182–183
Hyland K, Smith I, Bottigleri T, Perry J, Wendel U, Clayton PT, Leonard JV (1988) Demyelination and decreased 5-adenosylmethionine in 5,10-methylenetetra-hydrofolate reductase deficiency. Neurology 38: 459–462
Millot F, Chastagner P, Dhondt J, Sommelet D (1992) Substitutive therapy in a case of methotrexate neurotoxicity. Eur J Cancer 28A: 1935
Rees MM, Rodgers GM (1993) Homocystinemia: association of a metabolic disorder with vascular disease and thrombosis. Thromb Res 71: 337–359
Wang H, Yoshizumi M, Lai K, Tsai J-C, Perrella MA, Haber E, Lee ME (1997) Inhibition of growth and p21ras methylation in vascular endothelial cells by homocysteine but not cysteine. J Biol Chem 272 : 25380–25385
Griffiths R (1993) The biochemistry and pharmacology of excitatory sulphur-containing amino acids. Biochem Soc Trans 21: 66–72
Lipton SA, Rosenberg PA (1994) Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med 330: 613–622
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2000 Springer Basel AG
About this chapter
Cite this chapter
Kamen, B.A., Drachtman, R.I. (2000). The use of methotrexate in the treatment of childhood malignancies. In: Cronstein, B.N., Bertino, J.R. (eds) Methotrexate. Milestones in Drug Therapy. Birkhäuser, Basel. https://doi.org/10.1007/978-3-0348-8452-5_4
Download citation
DOI: https://doi.org/10.1007/978-3-0348-8452-5_4
Publisher Name: Birkhäuser, Basel
Print ISBN: 978-3-0348-9573-6
Online ISBN: 978-3-0348-8452-5
eBook Packages: Springer Book Archive